Avoid the paid bashers otherwise you will miss even a bigger rally in the works. FDA Panel of Doctors to meet in Q1 and we should be at $ 4 per share by then, upon approval easily at $ 7 to $ 8 and, on FDA stamp we will be double digits and then buyout could be as high #$%$ 40 if Medtronic bids.
I had predicted this move much earlier so I know what I am saying, we are going to $ 12 per share, read my posts and ignore paid bashers who are here to steal your shares.
Institutions are buying in large lots and will be doing so for the next few months, everyday, so penny traders are not able to keep up with selling. Watch as we soar to $ 12 per share.
Top, remember penny traders selling and institutions are loading up, matter of time before we explode back up as institutions have alot more money and results were superb.
Penny traders getting out while institutions loading up. I saw this on RMTI, stock did same thing before it soared to $ 15 per share from $ 3.75. Penny guys and traders have to leave first. Institutions will keep loading up as clinical results were great and no need to panic anymore. Sure they may need some money but any offering will be done at much higher prices. Also great buyout candidate. See at $ 12 per share.
Thanks, the fun has just begun.
Keep putting up the $ 12 post as people will understand and be able to calculate.
Lots but it was worth it. Imagine those poor people hearing that liar penny_dreaddful and having sold too early. What he did was pure criminal.
With such a limited float of just 36 million shares, rest is held by insiders and institutions, we should be at $ 12 per share within days, just like OXBT did with limited shares.
Today's news was bullish and clinical results were so strong that approval is becoming a certainty.
Load up as institutions are going to be all over this and they have just begun buying.
Best to hold, I have mines at $ 1.14, was early to see this. I expect quick rise to the $ 12 per share area. Hold on.
If you do 5X sales as buyout and first year sales are say $ 500 million, to be conservative, you are looking at a buyout price of $ 2.5 billion which is about $40 per share. This is definetly worth to buy and hold as buyout is a huge possibility per analyst, area is in demand.
Northland Capital Markets analyst Suraj Kalia was impressed with 18 month data for EnteroMedics (NASDAQ: ETRM) ReCharge trial and as a result more than doubled his price target from $3 to $7, suggesting nearly 300% upside from current trading levels of $1.80 (up 30%).
Kalia sees the strong data as leading to a positive FDA panel ruling. " Based on the current 18-month data, and barring any unforeseen kinks in any subgroup analysis (only top-line data has been released so far), we do not envision a mixed or negative ruling in an FDA panel," the analyst said.
The price target of $7 would give the company a $400 million market cap. The company could also find itself the target of a takeover, according to Kalila. "While we can articulate on DCF's as to how our PT was achieved, we believe that Enteromedics could now be a good takeout target post-approval and post-first few quarters of launch," the analyst said. "The diabetes and obesity space are usually high takeout multiple spaces, with premiums @ 5 - 10x forward sales."
For an analyst ratings summary and ratings history on EnteroMedics click here. For more ratings news on EnteroMedics click here.
Shares of EnteroMedics closed at $1.37 yesterday, with a 52 week range of $0.81-$3.23.
With great news that VBLOC device works at 18th months which is data FDA is looking at, with limited shares in ciriculation (small float), which institutions wanting to load up on ETRM before FDA and as quickly as possible, I expect us to jump dollars in the coming days as momentum heats up, much like it did with OXBT which went from $ 3 to $ 12 in a few days.
I expect same here, hold on, as stock is illiquid and surge in buyers will send this double digits.
Today's buyers were large institutions whom were waiting for 18th month data to load up since they wanted to see that device maintained weight loss over placebo not just at 12 months but at 18 months. As a matter of fact the results in the treatment arm have put to shame the results in the placebo arm. I expect more institutions to load up shortly as this goes to $ 12 per share.
Great news today. Shows with time VBLOC endures with weight loss as mental power in sham group dissolves.
VBLOC will easily be approved now. Going to $ 12 per share as predicted.
This is information for new investors. First of all I must say that I contacted the company to obtain some clarification on some issues. The obesity market costs taxpayers $ 147 billion per year and the government needs help to bring these costs down if they are going to one day reduce the deficit and balance the budget. The FDA has changed its guidelines on obesity pills and devices where they will now approve if there is benefit and safety versus risk. VBLOC which is the device belonging to ETRM reduced weight by 24.5% EWL with statistical significance of P = .002 versus placebo and, it has hypertension and diebetic benefits. This makes this device easily approvable once FDA Panel mets in Jan to Mar Quarter of 2014.
In terms of the device, it should retail for $ 10,000 and, the hospital stay is another $ 10,000. Insurance companies are going to flock to this device since it costs them millions of dollars to treat an obese person versus just $ 20,000 one time fee.
In terms of market in USA, 69% of US is either overweight or obese. Out of 330 million people it means 228 million is the target market. Now listen to this, if VBLOC gets just 1/10 of one tenth of 1% of this market which means .001, it means 227,000 patients. Now lets cut that amount even further say by 55% you get 100,000 patients per year. At $ 10,000 per patient you get $ 1 billion in Revenue per year.
In terms of earnings lets say they earn 15% of this to the bottom line, biotechs usually will have something like 40% or 50%, so you can see my numbers are conservative. 15% of $ 1 billion in revenue is $ 150 million in profit. If you have 60 million shares in circulation you have earnings per share of $ 2.50 per share.
Tell me, is it a good investment to buy a stock at $ 1.37 when it will earn $ 2.50 per share. Do you see risk?
About this penny_dreaddful person, he is a paid basher, either his hedge fund has bet the wrong way or is accumulating.